Related Experiment Video

Updated: Aug 16, 2026

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

Pulmonary involvement in microscopic polyangiitis

Christopher E Collins1, Francisco P Quismorio

  • 1Department of Internal Medicine, Division of Rheumatology and Immunology, University of Southern California Keck School of Medicine, Los Angeles, California, USA.

Current Opinion in Pulmonary Medicine
|August 12, 2005
PubMed
Abstract

Insights

Microscopic polyangiitis can affect the lungs, causing diverse symptoms and imaging findings. Early diagnosis and tailored treatments, including novel agents, improve patient outcomes.

Area of Science:

  • Pulmonary Medicine
  • Rheumatology
  • Immunology

Background:

  • Microscopic polyangiitis is a systemic necrotizing vasculitis impacting small vessels.
  • It frequently involves organs such as the kidneys and lungs, presenting a broad clinical spectrum.
  • Pulmonary involvement presents unique diagnostic and therapeutic challenges.

Purpose of the Study:

  • To review recent advancements in understanding the pathogenesis of pulmonary microscopic polyangiitis.
  • To summarize current clinical manifestations and diagnostic approaches for lung involvement.
  • To discuss evolving treatment strategies for pulmonary manifestations.

Main Methods:

  • Literature review of recent insights and observations.
  • Analysis of clinical presentations and diagnostic imaging findings.
  • Evaluation of current and emerging therapeutic modalities.

Main Results:

  • Pulmonary involvement ranges from interstitial fibrosis to hemoptysis due to capillaritis.
  • CT imaging shows diverse findings like ground-glass opacities, consolidation, and honeycombing.
  • Antineutrophil cytoplasmic antibodies (ANCA) are crucial for diagnosis, pathogenesis, and prognosis.
  • Therapeutic options include cyclophosphamide, rituximab, TNF-alpha blockers, plasmapheresis, and ventilatory support.

Conclusions:

  • Pulmonary manifestations of microscopic polyangiitis are varied and challenging.
  • Improved understanding enhances diagnostic accuracy and treatment efficacy.
  • Multidisciplinary management is key for successful patient outcomes.

More Related Videos

Microdissection and Immunofluorescence Staining of Myocardial Sleeves in Murine Pulmonary Veins08:52

Microdissection and Immunofluorescence Staining of Myocardial Sleeves in Murine Pulmonary Veins

Published on: November 21, 2023

Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet09:22

Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet

Published on: November 4, 2015

Related Concept Videos

Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.